Home » Newsletters » BioWorld Science

BioWorld Science

May 14, 2007

View Archived Issues

Promising preclinical activity of a novel HIV clade C vaccine

Novel therapeutic options for inflammatory disorders disclosed in recent patents

Altana discloses novel compounds for treating respiratory disorders

Immunosuppression: induction therapy with alemtuzumab

Phase I results encourage further clinical development of mapatumumab

Pregabalin reduces fibromyalgia pain

Recent advances in corneal transplantation therapy presented at the ARVO meeting

Vertex presents highlights of first quarter

In vitro activity of CLS-1506 against ocular bacterial, fungi and viral pathogens

GVAX immunotherapy for leukemia studied in three new trials

Study identifies effective dose of epinastine nasal spray for seasonal allergic rhinitis

Dainippon Sumitomo reports novel antidiabetic agents in recent patent

RG-1068 shows utility in MRI imaging of the pancreas

Conatus financing to support phase II trials of CTS-1027

ALTU-135 begins phase III trials in cystic fibrosis patients with pancreatic insufficiency

NovaThera and Gamida Cell collaborate in lung repair and regeneration

FDA requests Silenor carcinogenicity study results as part of NDA filing

KineMed gains option to SR-B1 as target in atherosclerotic heart disease

Dosing completes in two phase IIa obesity trials of oleoyl-estrone

Azedra studied in phase I/II trial for malignant pheochromocytoma

Preclinical proof-of-concept achieved for SC-75741 in influenza A

ImmunoCellular Therapeutics' brain tumor vaccine begins phase I trial

ProCertus BioPharm closes Series A financing

New financing completed at Morria Biopharmaceuticals

Enrollment completed in final phase II trial for Testosterone MD-Lotion

Axcan and NicOx end development of NCX-1000

Approvable letter issued by FDA for Merck & Co.'s CINV therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...